NEW YORK (GenomeWeb) – Synthetic biology startup Synlogic today announced it has raised $29.4 million in Series A financing.

Atlas Ventures and New Enterprise Associates led the round. Cambridge, Mass.-based Synlogic plans to use proceeds from the raise to further develop its microbial engineering platform for developing therapeutic microbes and advancing its preclinical pipeline across clinical applications, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.